Lansoprazole Use in Infants with GERD

Evidence Against Routine Use in Infants Under 1 Year

Lansoprazole should not be routinely given to infants with GERD, as it has been shown to be no more effective than placebo for symptom relief in this age group while significantly increasing the risk of serious adverse events, particularly lower respiratory tract infections 1
A multicenter, double-blind, randomized controlled trial involving 162 infants aged 1-12 months with GERD symptoms found no difference in efficacy between lansoprazole and placebo for symptom improvement 1
Serious adverse events, particularly lower respiratory tract infections, occurred significantly more frequently with lansoprazole than placebo (OR 6.56; 95% CI 1.18-26.25) 1

The American Thoracic Society recommends conservative management, including smaller, more frequent feedings to reduce gastric distension, as first-line treatment for infants with GERD 2
Thickening formula (if formula-fed), though caution is advised in preterm infants due to necrotizing enterocolitis risk, is also recommended as first-line treatment for infants with GERD 2
Maternal elimination diet (exclude milk and egg for 2-4 weeks if breastfeeding) is recommended as first-line treatment for infants with GERD 2
Trial of extensively hydrolyzed or amino acid-based formula if formula-fed is recommended as first-line treatment for infants with GERD 2
Upright positioning when awake and supervised is recommended as first-line treatment for infants with GERD 2

The risk-benefit ratio strongly favors avoiding PPI therapy in infants under 1 year due to increased risk of lower respiratory tract infections (6.56-fold increased odds) 1
Potential for community-acquired pneumonia, gastroenteritis, and candidemia is a concern with PPI use in infants 2
Long-term use of PPIs is associated with enterochromaffin cell hyperplasia, vitamin B12 deficiency, and bone fractures, though less relevant for short-term infant use 2

First-line treatment for all infants with GERD symptoms should include conservative measures such as feeding modifications, positioning, and dietary interventions for 2-4 weeks 2
If symptoms persist, re-evaluate diagnosis and consider referral to pediatric gastroenterology before initiating pharmacologic therapy 2, 3
Only consider off-label PPI use with informed consent regarding lack of proven efficacy and increased infection risk if severe, refractory disease with clear GI symptoms 1, 2
If PPI is initiated, re-evaluate response after 4-8 weeks and discontinue if no clear benefit 2

Do not prescribe PPIs for uncomplicated infant reflux or "fussiness" without clear GERD symptoms, as this represents overuse without proven benefit and exposes infants to unnecessary infection risk 1
Do not continue PPI therapy beyond 4-8 weeks without specialist consultation and re-evaluation of the diagnosis 2